C4X Discovery's () Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.
Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.
Meanwhile he says that their high-value, early-stage drug candidate designed to inhibit interleukin-17, has shown early encouraging signs in inflammation.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE